SCHEMBL3023620

SCHEMBL3023620

c1cc2oc3cnnc-3cc2s1

nearest known ligand 0.36

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30553739 0.68 METAP2 (0.50) GRM4
SCHEMBL5039726 0.67
SCHEMBL27977855 0.64 GPR35 (0.38)
SCHEMBL29488762 0.64 ALDH1A1 (0.48)
SCHEMBL5039552 0.63
SCHEMBL5039787 0.63
SCHEMBL18876250 0.63
SCHEMBL18876166 0.61 NPC1 (0.37)
SCHEMBL8014050 0.60 DYRK1A (0.49)
SCHEMBL5036547 0.59 HDAC6 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2507245-B1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC (US) 2017-04-12 EP disclosed
EP-2170903-B1 SPIRO[PIPERIDINE-4,4' -THIENO[3, 2-C]PYRAN]DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE SIGMA RECEPTOR FOR THE TREATMENT OF PSYCHOSIS ESTEVE LABOR DR (ES) 2012-09-05 EP disclosed
US-20100190813-A1 SPIRO [PIPERIDINE-4- 4' -THIENO [3,2-C] PYRAN] DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE SIGMA RECEPTOR FOR THE TREATMENT OF PSYCHOSIS OBERDORF CHRISTOPH 2010-07-29 US disclosed
US-20100190813-A1 SPIRO [PIPERIDINE-4- 4' -THIENO [3,2-C] PYRAN] DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE SIGMA RECEPTOR FOR THE TREATMENT OF PSYCHOSIS OBERDORF CHRISTOPH 2010-07-29 US disclosed
EP-2170903-A1 SPIRO ÝPIPERIDINE-4, 4' -THIENO Ý3, 2-C¨PYRAN¨DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE SIGMA RECEPTOR FOR THE TREATMENT OF PSYCHOSIS Laboratorios Del. Dr. Esteve, S.A. (ES) 2010-04-07 EP disclosed
EP-2170903-A1 SPIRO ÝPIPERIDINE-4, 4' -THIENO Ý3, 2-C¨PYRAN¨DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE SIGMA RECEPTOR FOR THE TREATMENT OF PSYCHOSIS Laboratorios Del. Dr. Esteve, S.A. (ES) 2010-04-07 EP disclosed
EP-2020414-A1 spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis Laboratorios del Dr. Esteve S.A. (ES) 2009-02-04 EP disclosed
EP-2020414-A1 spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis Laboratorios del Dr. Esteve S.A. (ES) 2009-02-04 EP disclosed
WO-2008155132-A1 SPIRO [PIPERIDINE-4, 4' -THIENO [3, 2-C] PYRAN] DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE SIGMA RECEPTOR FOR THE TREATMENT OF PSYCHOSIS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2008-12-24 WO disclosed
WO-2008155132-A1 SPIRO [PIPERIDINE-4, 4' -THIENO [3, 2-C] PYRAN] DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE SIGMA RECEPTOR FOR THE TREATMENT OF PSYCHOSIS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190813-A1 SPIRO [PIPERIDINE-4- 4' -THIENO [3,2-C] PYRAN] DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE SIGMA RECEPTOR FOR THE TREATMENT OF PSYCHOSIS SIGMAR1, OPRD1, OPRK1 GRM4 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.